Sanara MedTechSMTI
About: Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Employees: 141
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
380% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 5
29% more capital invested
Capital invested by funds: $24.5M [Q3] → $31.6M (+$7.13M) [Q4]
16% more funds holding
Funds holding: 44 [Q3] → 51 (+7) [Q4]
1.64% more ownership
Funds ownership: 9.26% [Q3] → 10.9% (+1.64%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Ross Osborn 18% 1-year accuracy 8 / 45 met price target | 61%upside $46 | Overweight Reiterated | 26 Mar 2025 |
HC Wainwright & Co. Yi Chen 28% 1-year accuracy 48 / 172 met price target | 78%upside $51 | Buy Maintained | 26 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SMTI published over the past 30 days









